Omalizumab for Severe Allergic Asthma Treatment:
Omalizumab is crucial in managing moderate-to-severe asthma mediated by human immunoglobulin E (IgE). Omalizumab is a recombinant humanized IgG1 monoclonal antibody drug that is specifically designed to target human immunoglobulin E (IgE). This action prevents the drug’s interaction with the high-affinity Fc-epsilon-RI receptor, generally found on mast cells, eosinophils, and basophils. This interaction plays a significant role in the allergic cascade.
Omalizumab received initial approval from the U.S. Food and Drug Administration (FDA) in 2003 to treat patients with moderate-to-severe asthma.
Uses/Indication:
Omalizumab is an FDA-approved therapeutic drug prescribed for treating moderate-to-severe persistent asthma in adults and pediatric patients aged 6 years or older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose signs and symptoms are not adequately controlled with inhaled corticosteroids.
Posology and Administration:
Available Dosage Forms: The therapeutic drug is available in three different dosage forms, which are as:
- Omalizumab 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2mL injection solution in a single-dose prefilled syringe.
- Omalizumab 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL solution in a single-dose prefilled autoinjector.
- Omalizumab 150 mg lyophilized powder in a single-dose vial for reconstitution.
Recommended Dosage: The recommended dosage of omalizumab to treat asthma is 75 mg to 375 mg, administered through a subcutaneous (SC) injection every 2 or 4 weeks. The appropriate dosage and frequency for omalizumab are specified by considering the patient’s weight and total IgE serum levels before treatment. No dosage adjustment is required based on total IgE levels taken during omalizumab treatment or in response to significant weight changes.
Potential Side Effects:
Omalizumab is generally considered well tolerated with an excellent safety profile. The most common side effects are mild or moderate including:
- Injection-site reactions
- viral infection
- sinusitis
- headache
- pharyngitis
- upper respiratory tract infection
Anaphylactic reactions may also be reported with omalizumab, typically occurring within 2 hours of the first or subsequent doses, although the incidence is low (0.1 to 0.2%).
Price-Cost, and Availability:
Omalizumab for subcutaneous use is an injectable prescription medicine that can be ordered from the Indian Generic Medicines (IGM) if it has not been approved or is not available in your country. Inquire today and we will help you calculate the total price to buy Omalizumab online legally and have the drug delivered to your location. From your end, we’ll need a prescription from your treating clinician. In some countries, we might also ask for an import license.
References:
https://www.xolairhcp.com/
https://www.ncbi.nlm.nih.gov/books/NBK545183/#:~:text=Omalizumab%20is%20an%20FDA%2Dapproved,adequately%20controlled%20with%20inhaled%20corticosteroids.
